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Yimplantation (90.0% vs. 89.4%, p¼0.659) were similar between two groups. There was
no difference in MACE rate and occurrence of stent thrombus between the two
groups (p¼NS), however, higher all-cause death rate in the ROTA group at 6 months,
1 and 2 years (p<0.05).
Conclusions: ROTA was used in patients with more lesion complexity. However, the
MACE rate was comparable between ROTA and CA at 6 months, 1 and 2 years.Clinical events
Cutting balloon
(n¼573)
Rotational atherectomy
(n¼413) p value
In-hospital Death/
QWMI/CABG
1.4% 2.0% 0.5166 monthAll-cause death (%) 2.7 7.1 0.007MI (%) 1.8 1.1 0.747TLR (%) 4.0 2.6 0.307Deﬁnite ST (%) 0.5 1.1 0.654Composite MACE 6.5 9.2 0.1841 yearAll-cause death (%) 4.7 10.3 0.007MI (%) 2.6 2.0 0.665TLR (%) 6.3 4.9 0.454Deﬁnite ST (%) 0.6 1.0 0.655Composite MACE (%) 10.6 14.5 0.1452 yearAll-cause death (%) 9.1 15.7 0.025MI (%) 4.5 3.2 0.499TLR (%) 10.3 8.4 0.496Deﬁnite ST (%) 0.7 1.4 0.655Composite MACE (%) 18.2 22.8 0.205MI: Myocardial infarction; QWMI: Q-wave myocardial infarction; CABG: Coronary artery bypass
grafting; TLR: Target lesion revascularization; ST: Stent thrombus; MACE: Major adverse cardiac
events.
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Clinical Impact of Diabetes Mellitus on Long-term Clinical Outcomes in Patients
Treated with Everolimus-Eluting Stent for Multivessel Percutaneous Coronary
Intervention
Lakshmana Pendyala, Joshua Loh, Al F. Omar, Sa’ar Minha, Marco DeMagalhaesPereira,
Hideaki Ota, Nevin Baker, Ricardo EscarcegaAlarcon, Radhika Gadesam,
Rebecca Torguson, Lowell Satler, Augusto Pichard, Ron Waksman
MedStar Heart Institute, Washington, DC
Background: Newer generation stents by means of more biocompatible components
limiting inﬂammatory response have led to signiﬁcant improvement in the cardio-
vascular outcomes.
Objective: The purpose of the present study is to evaluate the long term outcomes of
diabetic patients undergoing multivessel PCI with the use of everolimus-eluting stent
(EES).
Methods: 350 consecutive diabetic patients that underwent multivessel PCI deﬁned
as 2 vessel with EES during the same index procedure were analyzed. Patients were
further stratiﬁed by the need for insulin (n¼55) or oral medications only (n¼82) for
control of blood glucose in comparison once that were non-diabetic (n¼214). Primary
end point (MACE) was the combined incidence of death, and non-fatal Q-wave
myocardial and target vessel revascularization (TVR) at one year.
Results:Diabetic group had more African-Americans, and higher hypertension, renal
failure and higher body mass index compared to non-diabetics. At 1 year there was no
difference in rates of MACE, between the non-diabetics and oral diabetics (7% vs.
12%, p¼0.15) but the MACE rates were higher in insulin treated diabetics compared
to non-diabetics (24% vs. 7%, p<0.001). Similar trends were noted with TVR, with
no difference between non-diabetics and oral diabetics (4.3% vs. 10%, p¼0.09) but
signiﬁcantly higher TVR rate in the insulin group compared to non-diabetics (20% vs.4.3%, p<0.001). There were no differences in the over-all mortality and no cases of
deﬁnitive stent thrombosis were noted in the entire cohort at 1 year.
Conclusions: Despite the higher risk nature of multivessel intervention in diabetic
patients, with the use of newer generation EES stents, the event rates at one year in
oral-diabetics were similar to the non-diabetic population. But patients with insulin
treated diabetes continue to be a challenging population.Coronary
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Background: There are clinic and genetic polymorphism differences in coronary ar-
tery disease (CHD). Percutaneous coronary intervention (PCI), clinic, angiographic,
procedure technique may inﬂuence the evolution, major events (death, AMI, revas-
cularization) and clinical restenosis. This study aims to evaluate if there are genetic
polymorphism differences between patients with and without CHD and if it would
inﬂuence in long-term follow-up after PCI.
Method and Results: It was studied two groups: the coronary disease group (CDG)
with 182 patients of a closed health system with CHD that were submitted to PCI
from 2001 and 2007 and to genetic follow-up evaluation until 12/31/2008; the control
group (CG) with 36 patients, were angiographically normal and were also submitted to
genetic evaluation. The polymorphisms evaluated were the ACE I/D and A166C
(AT1R). In this period 221 procedures were performed in 182 patients of CDG. Qui
square, Fisher exact and Student t test were used. Cox multivariate regression analysis
were not performed because only three clinical characteristics and A166C had p<0.10
in univariable analysis.
The CG and CDG patients were: female 20 (55.6%) and 49 (26.9%), (P¼0.0007);
age 55.911.1 and 60.810.5 (P¼0.0100); tobacco smokers 5 (13.9%) and 67
(36.8%), (P¼0.0132); diabetes 4 (11.1%) and 48 (26.4%), (P¼0.0802); hypertension
29 (80.6%) and 146 (80.2%), (P¼0.9631); dyslipidemia 14 (38.9%) and 112 (61.5%),
(P¼0.0119); family history 12 (33.3%) and 60 (33.0%), (P¼0.9659); obesity 9 (25.0%)
and 60 (33.0%), (P¼0.3476); ACE polymorphism DD 16 (44.5%), DI 17 (47.2%), II
3 (8.3%) and DD 81 (44.5%), DI 70 (38.5%), II 31 (17.0%), (P¼0.3612); A166C
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Ypolymorphism AA 36 (100.0), AC 0 (0.0%), CC 0 (0.0%) and AA 135 (74.2%), 42
(23.1%), 5 (2.7%), (P¼0.0026). In CDG there were no difference: between ACE and
A166C polymorphism at one, two or three vessel disease; between majors events,
deaths, AMI and revascularization; and between restenosis and the mean vessel
diameter, lesion extension and bare metal or drug eluting stents.
Conclusions: It was demonstrated that CDG were genetically A166C polymorphism
different from normal CG who did not have CC and AC. CDG were older with more
males gender, smokers and dyslipidemia in contrast with CG. There were no differ-
ences between the studied variables, illness extension, major events and restenosis in
the CDG. Cox multivariable analysis were not performed as in univariable analysis
only three variables have shown p<0.10.
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Prognostic Value of Interlukin 6 in Young Adults Presenting with
Acute Coronary Syndrome
Ahmed Mowafy, Hazem Ramadan, Ashraf Hussien, Ahmed Abd El Hay
Cairo University, Cairo, Egypt
Background: The role of inﬂammation in the progression of coronary artery disease
(CAD), even in the absence of myocardial necrosis is often overlooked. This increased
our interest to evaluate the prognostic value of the inﬂammatory marker, IL-6 in young
patients with ACS and evaluating its role in predicting CAD severity, clinical course
and mortality.
Methods: A total of 140 young patients (18-40 years old) presented with acute chest
pain, were included in this randomized prospective study. They were subjected to a)
full clinical evaluation including Kilip class evaluation, b) Laboratory evaluation
including cardiac markers and IL-6 level analysis c) 12 leads ECG and Echocardi-
ography and d) coronary angiography. The patients were divided into 2 groups, pa-
tients with acute chest pain and positive coronary angiography (110 patients), and
those with normal coronary angiography (control group, 30 patients).
Results: The IL-6 level was signiﬁcantly higher in patients with documented CAD
compared to the control group (39.562.5 Vs 3.830.79 p<0.001). Detailed evalu-
ation of the coronary angiography results showed IL-6 level was signiﬁcantly higher in
patients with signiﬁcant lesions who needed to perform PCI (92 patients) than pa-
tients with non-signiﬁcant atherosclerotic plaques needing just medical treatment (18
patients) (45.523.17 Vs 9.221.93 p<0.001). Clinical Comparison of the diversity
of the ACS patients showed higher level of IL-6 in STEMI patients (63 Pts 57%)
than NSTEMI (23 Pts 21%) and UA (24 Pts 22%) (49.5623 Vs 43.517 Vs
9.52.53 respectively with p<0.001). There was positive correlation between IL-6
level and number of affected vessels (r¼0.341, p<0.001), and highly signiﬁcant
negative correlation between IL-6 level and TIMI Flow (Pre PCI) (r ¼ - 0.348, p<
0.001). ROC curve was calculated for the use of IL-6 level as a predictor of morbidity
and mortality with cutoff value of 41 pg/ml with a sensitivity of 100 %, speciﬁcity of
66%, and positive predictive value of 25%, negative predictive value of 100% and the
diagnostic accuracy of 69 %. The optimal cutoff value for IL-6 level to predict mor-
tality was 71 pg/ml with a sensitivity of 100%, speciﬁcity of 89 %, positive predictive
value ¼ 20 %, negative predictive value ¼ 100 % and the diagnostic accuracy ¼ 89 %.
Conclusion: The use of IL-6 as a prognostic marker for ACS may be of Value; it may
predict the severity of CAD as well as the mortality and morbidity of young patients
with acute coronary syndrome.
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TIMI Risk Score Can Be Used for Choosing Treatment Strategy in Patients with Cocaine
Associated Chest Pain
Saurabh Rajpal, Ashish Dwary, Andres Vargas, Shivang Shah, Anderson Penuela,
Nuri I. Akkus
Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA
Purpose: To determine value of TIMI risk score in evaluation of patients admitted
with cocaine associated chest pain (CACP).Introduction: It has been shown that in patients with unstable angina/Non-ST
Elevation myocardial infarction (NSTEMI), the TIMI risk score categorizes a pa-
tient’s risk of death, ischemic events and helps to identify individuals who should be
treated with an early invasive strategy. CACP even with NSTEMI can be due to
coronary vasoconstriction/increased demand and does not necessarily indicate under-
lying coronary artery disease (CAD). We sought to investigate the usefulness of TIMI
risk score in patients with CACP.
Methods: Retrospectively data of 84 consecutive patients who presented with CACP
with urine positive screen in the years 2002-2010 were analyzed. TIMI risk score was
calculated by reviewing the admission chart. Obstructive CAD was deﬁned as; more
than 70% narrowing in one of the epicardial arteries, Positive stress test (PST) was
deﬁned as an abnormal nuclear scan showing ischemia at least in one vessel territory.
Non-obstructive CAD was deﬁned as negative nuclear stress test or non obstructive
CAD by coronary angiogram (CA).
Results: Among 84 patients, 52 were classiﬁed as low risk (score 0, 1) and 32 as
intermediate/ high risk ( 2) TIMI risk score. 96% of patients in the low TIMI risk
group did not have positive stress test or obstructive CAD in CA. 83% of patients with
obstructive CAD or PST had intermediate/high TIMI risk score. Chi square test
revealed that TIMI risk score was signiﬁcantly higher in obstructive CAD/PST pa-
tients compared to non obstructive CAD group (Chi sq 12.15, DIF¼1, p¼0.01, Odds
Ratio¼11.364).
Conclusion: In hospitalized patients with CACP, TIMI risk score can be used to
predict presence or absence of obstructive CAD and can assist in decision of invasive
or non-invasive treatment strategy.
CRT-149
Differential Cost Analysis of 4 French Femoral Approach Revealed Significant Savings
Over Radial Approach for Diagnostic Catheterization
Xiaomei Lin, Kenneth Khaw
AtlantiCare Regional Med Ctr., Pomona, NJ
Background: Approximately one million diagnostic cardiac catheterizations are
performed annually. The Accountable Care Act means that cost savings measures
are becoming increasingly more important. Through advances in ﬂat panel X-ray
in the cath lab, coronary arteriogram quality has signiﬁcantly improved for 4French
(4F) catheters to allow for daily use in arteriography. Previous Transradial Artery
Approach (TRA) studies revealed greater cost effectiveness for TRA due to post
procedure care. Studies with 4F Femoral Approach (4FFA) revealed hemostatic
devices are never used and patients are able to ambulate in one hour. Post pro-
cedure care between 4FFA and TRA are similar and can be compared on equip-
ment used.
Methods: To compare cost of both approaches, we analyzed the equipment used for
4FFA and TRA through cost analysis, as most institutions use similar basic packs for
both. List prices were analyzed. Costs per 1000 patients were calculated. Accepted
practice recognizes that two-three diagnostic catheters are generally used for 4FFA and
TRA.
Results: For 4FFA, a small injection syringe (8ml - $6) is needed. For TRA,
Micropuncture kit ($46.80), Glide wire ($33.80),TR Band ($32.50), verapamil 2ml
($1.76), nitroglycerine 10 ml ($0.67) and heparin 10ml ($9.09) are used adding
additional costs totaling ($124.62). The equipment cost of 4FFA is 2000% less than
TRA. Depending on cardiologist equipment preferences, the equipment may be more
or less. Recovery time is not affected and post-procedure complications remain the
same at our institution.
If TRA is completely adopted, there would be an additional cost expense of
$124,620/1000 pts, however, if 4FFA is completely adopted, there would be addi-
tional cost expense of $6,000/1000 pts resulting in a total cost savings of $118,620/
1000 pts. Fixed and variable costs differ as per institutional purchasing contracts and
patient referral sources.
Conclusion: Adoption of 4FFA can save money for institutions performing diag-
nostic cardiac catheterizations. Potential savings equate to $118 million for the switch
in the United States.
